Joint development advice from the US Food and Drug Administration and European Medicines Agency on generic drugs has the potential to push both regulators to align their standards, and the potential for faster and cheaper drug approvals globally excites industry.
The grand dream, which could save sponsors millions by preventing duplicative clinical studies and unnecessary testing, likely is a long...






